Documente Academic
Documente Profesional
Documente Cultură
Ulcerative colitis is a chronic disease with recurrent symptoms and significant morbidity. The
precise etiology is still unknown. As many as 25 percent of patients with ulcerative colitis have
extraintestinal manifestations. The diagnosis is made endoscopically. Tests such as perinuclear
antineutrophilic cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies are
promising, but not yet recommended for routine use. Treatment is based on the extent and
severity of the disease. Rectal therapy with 5-aminosalicylic acid compounds is used for proctitis. More extensive disease requires treatment with oral 5-aminosalicylic acid compounds
and oral corticosteroids. The side effects of steroids limit their usefulness for chronic therapy.
Patients who do not respond to treatment with oral corticosteroids require hospitalization and
intravenous steroids. Refractory symptoms may be treated with azathioprine or infliximab.
Surgical treatment of ulcerative colitis is reserved for patients who fail medical therapy or who
develop severe hemorrhage, perforation, or cancer. Longstanding ulcerative colitis is associated
with an increased risk of colon cancer. Patients should receive an initial screening colonoscopy eight years after the onset of pancolitis and 12 to 15 years after the onset of left-sided disease; follow-up colonoscopy should be repeated every two to three years. (Am Fam Physician
2007;76:1323-30, 1331. Copyright 2007 American Academy of Family Physicians.)
This article exemplifies the AAFP 2007 Annual
Clinical Focus on management of chronic illness.
Epidemiology
Ulcerative colitis affects approximately
250,000 to 500,000 persons in the United
States, with an annual incidence of two to
seven per 100,000 persons. The overall incidence of the disease has remained constant
over the past five decades.2 The financial
cost is nearly $500 million annually, and the
disease accounts for 250,000 physician visits
and 20,000 hospitalizations per year.3
The onset of ulcerative colitis is most
common between 15 and 40 years of age,
with a second peak in incidence between
50 and 80 years. The disease affects men and
women at similar rates. The precise etiology
Downloaded from the American Family Physician Web site at www.aafp.org/afp. Copyright 2007 American Academy of Family Physicians. For the private, noncommercial
use of one individual user of the Web site. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
Ulcerative Colitis
Evidence
rating
References
22
23
28
31
1, 34
Extraintestinal manifestation
Frequency
(%)*
Osteoporosis
Oral ulcerations
Arthritis
Primary sclerosing cholangitis
Uveitis
Pyoderma gangrenosum
Deep venous thrombosis
Pulmonary embolism
15.0
10.0
5.0 to 10.0
3.0
0.5 to 3.0
0.5 to 2.0
0.3
0.2
www.aafp.org/afp
The clinical history can be used to differentiate the various etiologies of chronic diarrhea in patients who have not previously
been diagnosed with ulcerative colitis. For
example, recent antibiotic use might suggest
pseudomembranous colitis; recent travel
may indicate infectious colitis; and abdominal pain that is relieved with bowel movements could represent IBS.
For the patient with established ulcerative
colitis, the presence of constitutional symptoms and extraintestinal manifestations,
particularly arthritis and skin lesions, may
Volume 76, Number 9
November 1, 2007
Ulcerative Colitis
Mild disease
Moderate disease
Severe disease
Normal
Normal
< 4 per day
< 20
Normal
< 90
None
< 3.0
> 100F
> 6 per day
> 30
< 30
> 100
> 10
Clinical characteristics
Crohns colitis
Infectious colitis
Irritable bowel syndrome
Ischemic colitis
Pseudomembranous
colitis
Information from reference 12.
www.aafp.org/afp
Ulcerative Colitis
Crohns disease
Abdominal pain
Depth of
inflammation
Diarrhea
Distribution
Variable
Mucosal
Common
Transmural
Severe
Diffuse, contiguous
spread; always
involves rectum;
spares proximal
gastrointestinal tract
Rare
Less severe
Segmental, noncontiguous
spread (skip lesions);
less common rectal
involvement; occurs in
entire gastrointestinal tract
Common
Test combination
pANCA only positive
pANCA positive plus
ASCA negative
Sensitivity
(%)
Specificity
(%)
LR+*
LR
55.3
70.3
88.5
93.4
4.6
10.0
0.5
0.3
The sensitivity, specificity, and LR in the referenced study were derived from a
subgroup of children and may not be applicable to an adult population.
note:
pANCA = perinuclear antineutrophilic cytoplasmic antibody; ASCA = anti-Saccharomyces cerevisiae antibody; LR+ = positive likelihood ratio; LR = negative likelihood ratio.
*Increasing values mean the test is better at ruling in disease when positive.
Decreasing values (i.e., less than 1) mean the test is better at ruling out disease
when negative.
Information from reference 18.
Treatment
medical management
Feature
www.aafp.org/afp
November 1, 2007
Ulcerative Colitis
Proctitis
Mild to moderate
Moderate to severe
Left-sided
Extensive
5-ASA suppositories
Oral 5-ASA
Response?
Response?
Yes
Complications
(i.e., perforation,
severe hemorrhage,
and toxic megacolon
No
Urgent surgical
consultation
Yes
Rectal 5-ASA
maintenance
No
Oral 5-ASA
maintenance
Oral steroids
Response?
Yes
No
Taper steroids
Hospitalize to receive
intravenous corticosteroids
Consider 5-ASA
prophylaxis
Response?
Yes
Convert to oral steroids,
taper dosage as outpatient
No
Consider referral for therapy
with cyclosporine (Sandimmune)
or infliximab (Remicade)
Figure 1. Algorithm for the treatment of ulcerative colitis. (5 ASA = 5-aminosalicylic acid.)
Information from references 1, 7, and 19.
Ulcerative Colitis
Table 6. Common Medical Therapies for Patients with Ulcerative Colitis
Medication
5-aminosalicylic acid
Sulfasalazine
(Azulfidine)
Mesalamine
(Asacol, Pentasa)
Mesalamine enema
(Rowasa)
Daily dosage*
Approximate cost
2 to 6 g
Prednisone
40 to 60 mg
Steroid enema
100 mg
Diarrhea
Azathioprine
(Imuran)
Mercaptopurine
(Purinethol)
Infliximab (Remicade)
5 mg per kg
note: Listed
with standard therapy using 5-ASA compounds and corticosteroids for patients with
severe ulcerative colitis (two studies with a
total of 50 patients); information about longterm results and costs is not available.25
In two recent clinical trials, 60 percent of
patients who failed to respond to corticosteroid therapy achieved symptom remission with infliximab (Remicade), a chimeric
monoclonal antibody that neutralizes the
proinflammatory cytokine tumor necrosis factor-, compared with approximately
30percent of patients who received placebo.26
Patients who fail to respond to maximal
medical therapy are candidates for surgical
therapy (see Surgical Management section).
The level of therapy that induces remission
dictates the selection of maintenance therapy. Patients who achieve remission solely
with 5-ASA compounds may remain on
these same medications, although typically
at lower dosages.27 If response is obtained
with azathioprine (Imuran) or infliximab,
these medications are continued to maintain remission.
If steroids are required to induce remission,
higher dosages of 5-ASA are often needed.
1328 American Family Physician
www.aafp.org/afp
No prospective randomized trials have compared medical treatment to surgery for any
indication in patients with ulcerative colitis.7
Colectomy for the treatment of ulcerative
colitis is warranted in patients who develop
dysplasia or cancer (see Cancer Screening
section); who have disease resistant to maximal medical therapy; or who experience
massive hemorrhage, perforation, or toxic
megacolon.19 Toxic megacolon, which is a
presentation of fulminant ulcerative colitis,
is characterized by dilation of the transverse
Volume 76, Number 9
November 1, 2007
Ulcerative Colitis
colon to more than 5.5 cm on supine abdominal radiography and requires emergent surgical evaluation.19
Surgical treatment of ulcerative colitis is
curative and has been shown to lead to durable improvements in quality of life.29 However, potential complications include bowel
obstruction, pouchitis, stricture, pouch dysfunction, and the possibility of decreased
fertility in women.19
complementary therapy
The Authors
ROBERT C. LANGAN, MD, is the program director of St.
Lukes Family Medicine Residency in Bethlehem, Pa. He
received his medical degree from Albany (N.Y.) Medical
College, and completed a residency in family medicine at
the Naval Hospital Pensacola, Fla.
PATRICIA B. GOTSCH, MD, FAAFP, is clinical faculty at St.
Lukes Family Medicine Residency. She received her medical degree from Johns Hopkins School of Medicine, Baltimore, Md., and completed a residency in family medicine
at Hinsdale (Ill.) Hospital.
MICHAEL A. KRAFCZYK, MD, FAAFP, is clinical faculty
at St. Lukes Family Medicine Residency. He received his
medical degree from Temple University School of Medicine, Philadelphia, Pa. He completed a residency in family
medicine at DeWitt Army Community Hospital, Fort Belvoir, Va., and a sports medicine fellowship at St. Lukes
Hospital, Bethlehem.
DAVID D. SKILLINGE, DO, FAAFP, is the osteopathic program director of St. Lukes Family Medicine Residency. He
received his medical degree from the Philadelphia (Pa.)
College of Osteopathic Medicine, and completed a residency in family medicine at St. Lukes Hospital.
Address correspondence to Robert C. Langan, MD, St.
Lukes Family Medicine Residency, 2830 Easton Ave., Bethlehem, PA 18017 (e-mail: langanr@slhn.org). Reprints are
not available from the authors.
Author disclosure: Nothing to disclose.
REFERENCES
1. Carter MJ, Lobo AJ, Travis SP, for the IBD Section, British
Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut
2004;(53 suppl 5):V1-16.
2. Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine
WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in
Olmstead County, Minnesota, 1940-1993: incidence,
prevalence, and survival. Gut 2000;46:336-43.
www.aafp.org/afp
Ulcerative Colitis
www.aafp.org/afp
21. Fitzgerald JM, Marsh TD. Mesalamine in ulcerative colitis. DICP 1991;25:140-5.
22. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi
M, Woogen S, et al. Delayed-release oral mesalamine at
4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J
Gastroenterol 2005;100:2478-85.
23. Gionchetti P, Rizzello F, Venturi A, Ferretti M, Brignola
C, Miglioli M, et al. Comparison of oral with rectal
mesalazine in the treatment of ulcerative proctitis. Dis
Colon Rectum 1998;41:93-7.
24. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A
meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-76.
25. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser
K. Cyclosporine A for induction of remission in severe
ulcerative colitis. Cochrane Database Syst Rev 2005;(1):
CD004277.
26. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W,
Olson A, Johanns J, et al. Infliximab for induction and
maintenance therapy for ulcerative colitis [Published
correction appears in N Engl J Med 2006;354:2200]. N
Engl J Med 2005;353:2462-76.
27. Sachar DB. Maintenance therapy in ulcerative colitis and
Crohns disease. J Clin Gastroenterol 1995;20:117-22.
28. Recommendations for the prevention and treatment
of glucocorticoid-induced osteoporosis: 2001 update.
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis
Rheum 2001;44:1496-503.
29. Thirlby RC, Sobrino MA, Randall JB. The long-term
benefit of surgery on health-related quality of life in
patients with inflammatory bowel disease. Arch Surg
2001;136:521-7.
30. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC,
Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG
in maintaining remission of ulcerative colitis. Aliment
Pharmacol Ther 2006;23:1567-74.
31. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak
M, et al. Maintaining remission of ulcerative colitis with
the probiotic Escherichia coli Nissle 1917 is as effective
as with standard mesalazine. Gut 2004;53:1617-23.
32. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers
DM, Axon AT. Non-pathogenic Escherichia coli versus
mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
33. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut
2001;48:526-35.
34. Smith RA, von Eschenbach AC, Wender R, Levin B, Byers
T, Rothenberger D, et al., for the ACS Prostate Cancer
Advisory Committee, ACS Colorectal Cancer Advisory
Committee, and ACS Endometrial Cancer Advisory
Committee. American Cancer Society guidelines for
the early detection of cancer: update of early detection
guidelines for prostate, colorectal, and endometrial
cancers [Published correction appears in CA Cancer J
Clin 2001;51:150]. CA Cancer J Clin 2001;51:38-75.
35. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk:
a systematic review and metaanalysis of observational
studies. Am J Gastroenterol 2005;100:1345-53.
November 1, 2007